Intercept Pharmaceuticals, Inc.
ICPTDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001270073
Intercept Pharmaceuticals, Inc. was delisted in 2023; its insiders filed their last Form 4 on Nov 13, 2023; 146 institutions reported holding it in 13F filings for Q3 2023, worth $724.6M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 146
- Q3 2023, +22 vs. previous quarter
- 13F value
- $724.6M
- Reported value at the end of Q3 2023
- Superinvestors holding
- 0
- At the end of Q3 2023
Superinvestors holding ICPT, Q3 2023
No superinvestor reported holding ICPT at the end of Q3 2023.
Latest insider trades
Open-market purchases and sales by Intercept Pharmaceuticals, Inc. insiders from Form 4, newest first.
No open-market purchases or sales by Intercept Pharmaceuticals, Inc. insiders are on file.
Top 10 13F holders, Q3 2023
The largest institutional positions in Intercept Pharmaceuticals, Inc. at the end of Q3 2023; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 4,212,820 | $78.1M | 0.00% | −184,150−4.2% | Reduced |
| State Street Corp | 3,197,810 | $59.3M | 0.00% | −982,414−23.5% | Reduced |
| UBS Group AG | 2,999,188 | $55.6M | 0.03% | +1,639,717+120.6% | Added |
| Magnetar Financial LLC | 2,407,209 | $44.6M | 1.14% | +2,407,209 | New |
| Alpine Associates Management Inc. | 2,203,295 | $40.8M | 2.14% | +2,203,295 | New |
| Deerfield Management Company, L.P. (Series C) | 2,077,893 | $38.5M | 0.85% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,071,232 | $38.4M | 0.00% | −2,622,585−55.9% | Reduced |
| Jefferies Financial Group Inc. | 2,000,000 | $37.1M | 0.92% | +2,000,000 | New |
| Alliancebernstein L.P. | 1,542,896 | $28.6M | 0.01% | +1,482,206+2,442.3% | Added |
| Pictet Asset Management Holding SA | 1,205,093 | $22.3M | 0.03% | +1,205,093 | New |